Skip to main navigation
Skip to search
Skip to main content
Utrecht University Home
Help & FAQ
Home
People
Research units
Research output
Activities
In the media
Prizes & Grants
Search by expertise, name or affiliation
What Happens To Originator Medicines When (Generic) Followers Enter The Public Market
C. Habl,
Christine Leopold
Austria Public Health Institute GÖG, Vienna
Harvard Medical School & Harvard Pilgrim Institute, Boston, MA
Research output
:
Contribution to journal
›
Meeting Abstract
›
Academic
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'What Happens To Originator Medicines When (Generic) Followers Enter The Public Market'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Atorvastatin
40%
Bulgaria
20%
Clopidogrel
40%
Czech Republic
20%
Delisting
60%
Dissemination Strategy
20%
Estonia
100%
European Countries
20%
External Reference Pricing
20%
Feature Information
20%
Generic Entry
20%
Generic Market
20%
Hungary
20%
Iceland
20%
Latvia
20%
Market Entry
20%
National Formulary
40%
Off-patent
20%
Olanzapine
40%
Omeprazole
20%
Originator Brand
40%
Paroxetine
20%
Pfizer
20%
Pharmaceutical Companies
20%
Poland
40%
Pricing Regulations
20%
Public Markets
100%
Publicly Funded
20%
Slovakia
20%
Valproic Acid
20%
Pharmacology, Toxicology and Pharmaceutical Science
Atorvastatin
100%
Clopidogrel
100%
Olanzapine
100%
Omeprazole
50%
Paroxetine
50%
Sodium Valproate
50%